fariqsaid personal page - To The Moon

fariqsaid

No personal profile

2Follow

1Followers

0Topic

0Badge

2022-01-14

Nice

WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool

2022-01-09

It should eventually

Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?

2022-01-07

Might be the dip before another massive spike

Bitcoin Drops Below $42,000 to Lowest Level Since September

2022-01-06

Nice

Sorry, the original content has been removed

2022-01-06

Sounds fun

Disney Allowed To Create Its Own Metaverse At Theme Parks

2022-01-05

Worrying

Sorry, the original content has been removed

2022-01-04

Cool

5 Stocks To Watch For January 4, 2022

2022-01-04

Cool

5 Stocks To Watch For January 4, 2022

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4104376232081940","uuid":"4104376232081940","gmtCreate":1641273163531,"gmtModify":1641273163531,"name":"fariqsaid","pinyin":"fariqsaid","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":2,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9005038359,"gmtCreate":1642118941195,"gmtModify":1676533682755,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005038359","repostId":"2203179956","repostType":4,"repost":{"id":"2203179956","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1642116616,"share":"https://ttm.financial/m/news/2203179956?lang=&edition=fundamental","pubTime":"2022-01-14 07:30","market":"us","language":"en","title":"WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool","url":"https://stock-news.laohu8.com/highlight/detail?id=2203179956","media":"Reuters","summary":"A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKl","content":"<html><head></head><body><p>A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.</p><p>WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.</p><p>The panel on Thursday strongly recommended Lilly&#39;s baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir&#39;s antibody therapy for non-severe patients at the highest risk of hospitalization.</p><p>So far, GSK-Vir&#39;s monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> offered lower protection in such tests.</p><p>The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body&#39;s natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.</p><p>The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.</p><p>French medical charity Medecins Sans Frontieres <a href=\"https://laohu8.com/S/MSF\">$(MSF)$</a> welcomed the United Nations agency&#39;s guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.</p><p>MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-14 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.</p><p>WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.</p><p>The panel on Thursday strongly recommended Lilly&#39;s baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir&#39;s antibody therapy for non-severe patients at the highest risk of hospitalization.</p><p>So far, GSK-Vir&#39;s monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> offered lower protection in such tests.</p><p>The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body&#39;s natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.</p><p>The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.</p><p>French medical charity Medecins Sans Frontieres <a href=\"https://laohu8.com/S/MSF\">$(MSF)$</a> welcomed the United Nations agency&#39;s guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.</p><p>MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","VIR":"Vir Biotechnology, Inc.","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4007":"制药","BK4535":"淡马锡持仓","BK4532":"文艺复兴科技持仓","LLY":"礼来","BK4551":"寇图资本持仓","BNTX":"BioNTech SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203179956","content_text":"A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.The panel on Thursday strongly recommended Lilly's baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir's antibody therapy for non-severe patients at the highest risk of hospitalization.So far, GSK-Vir's monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and Regeneron Pharmaceuticals offered lower protection in such tests.The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body's natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.French medical charity Medecins Sans Frontieres $(MSF)$ welcomed the United Nations agency's guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006654316,"gmtCreate":1641729568056,"gmtModify":1676533643182,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"It should eventually&nbsp;","listText":"It should eventually&nbsp;","text":"It should eventually","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006654316","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://ttm.financial/m/news/1198290127?lang=&edition=fundamental","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<html><head></head><body><p>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><b>AAPL: the bull case</b></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><b>AAPL: the bear case</b></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><b>The Apple Maven’s take</b></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-09 12:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple...</p>\n\n<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008774856,"gmtCreate":1641540591984,"gmtModify":1676533627233,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Might be the dip before another massive spike","listText":"Might be the dip before another massive spike","text":"Might be the dip before another massive spike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008774856","repostId":"1198673233","repostType":4,"repost":{"id":"1198673233","kind":"news","pubTimestamp":1641537463,"share":"https://ttm.financial/m/news/1198673233?lang=&edition=fundamental","pubTime":"2022-01-07 14:37","market":"us","language":"en","title":"Bitcoin Drops Below $42,000 to Lowest Level Since September","url":"https://stock-news.laohu8.com/highlight/detail?id=1198673233","media":"Bloomberg","summary":"Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since Septem","content":"<html><head></head><body><p>Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.</p><p>The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% from its record near $69,000 reached Nov. 10. Second-largest Ether dropped as much as 8.3% to its lowest level since Sept. 30.</p><p>The retreat comes after minutes from the Federal Reserve’s December meeting, published Wednesday, flagged the chance of earlier- and faster-than-expected rate hikes as well as potential balance-sheet rundown.</p><p>“The Fed’s intention to reduce the balance sheet in Q1 2022 is the primary cause of this sell-off,” Fundstrat strategists said in a note Thursday. “Unfortunately, no immediate support looks likely ahead of September 2021 lows at $39,573, with breaks of that leading down to last summer’s May-July bottom.”</p><p><img src=\"https://static.tigerbbs.com/41d898d24996b0fecf381b56b677bbcf\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"/></p><p>Bitcoin gained about 60% last year, outperforming other asset classes amid a narrative that included institutional adoption, inflation protection and investment diversification. It’s struggled in recent weeks, though, amid a volatile period for financial markets. Spiking inflation is leading central banks to tighten monetary policy, threatening to reduce the liquidity tailwind that lifted a wide range of assets.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin Drops Below $42,000 to Lowest Level Since September</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin Drops Below $42,000 to Lowest Level Since September\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 14:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198673233","content_text":"Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% from its record near $69,000 reached Nov. 10. Second-largest Ether dropped as much as 8.3% to its lowest level since Sept. 30.The retreat comes after minutes from the Federal Reserve’s December meeting, published Wednesday, flagged the chance of earlier- and faster-than-expected rate hikes as well as potential balance-sheet rundown.“The Fed’s intention to reduce the balance sheet in Q1 2022 is the primary cause of this sell-off,” Fundstrat strategists said in a note Thursday. “Unfortunately, no immediate support looks likely ahead of September 2021 lows at $39,573, with breaks of that leading down to last summer’s May-July bottom.”Bitcoin gained about 60% last year, outperforming other asset classes amid a narrative that included institutional adoption, inflation protection and investment diversification. It’s struggled in recent weeks, though, amid a volatile period for financial markets. Spiking inflation is leading central banks to tighten monetary policy, threatening to reduce the liquidity tailwind that lifted a wide range of assets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008267150,"gmtCreate":1641462272566,"gmtModify":1676533617627,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008267150","repostId":"1179623263","repostType":4,"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008628705,"gmtCreate":1641434443039,"gmtModify":1676533615138,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Sounds fun","listText":"Sounds fun","text":"Sounds fun","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008628705","repostId":"1127622369","repostType":4,"repost":{"id":"1127622369","kind":"news","pubTimestamp":1641432970,"share":"https://ttm.financial/m/news/1127622369?lang=&edition=fundamental","pubTime":"2022-01-06 09:36","market":"us","language":"en","title":"Disney Allowed To Create Its Own Metaverse At Theme Parks","url":"https://stock-news.laohu8.com/highlight/detail?id=1127622369","media":"TheStreet","summary":"Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The ","content":"<html><head></head><body><p>Walt Disney received federal approval for a patent to create a virtual world at its theme parks.</p><p>The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to create its own virtual reality space at its theme parks.</p><p>Disney said the patent will be used to create a virtual world at its brick and mortar venues such as inside a theme park or Disney property.</p><p>The entertainment company already has over 300 patents that are used for its ride systems, live entertainment, interactive technology, special effects, fiber optics and advanced audio systems.</p><p>The metaverse is gaining traction among tech companies such as Meta Platforms (formerly Facebook) FB, Google, Apple and Microsoft.</p><p>Disney&#39;s patent could allow the entertainment company to make a virtual world simulator throughout the park and potentially include &#34;a handheld device configured for use by a user in the real-world venue and communicatively coupled to the computing platform.&#34;</p><p>The patent could include the use of mutiple projectors to shine animated or visual image onto 3-D objects instead of the typical two dimensional being used currently.</p><p>This technology means that customers would not have to use a virtual reality headset or augmented reality glasses to view the images.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Allowed To Create Its Own Metaverse At Theme Parks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Allowed To Create Its Own Metaverse At Theme Parks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to ...</p>\n\n<a href=\"https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127622369","content_text":"Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to create its own virtual reality space at its theme parks.Disney said the patent will be used to create a virtual world at its brick and mortar venues such as inside a theme park or Disney property.The entertainment company already has over 300 patents that are used for its ride systems, live entertainment, interactive technology, special effects, fiber optics and advanced audio systems.The metaverse is gaining traction among tech companies such as Meta Platforms (formerly Facebook) FB, Google, Apple and Microsoft.Disney's patent could allow the entertainment company to make a virtual world simulator throughout the park and potentially include \"a handheld device configured for use by a user in the real-world venue and communicatively coupled to the computing platform.\"The patent could include the use of mutiple projectors to shine animated or visual image onto 3-D objects instead of the typical two dimensional being used currently.This technology means that customers would not have to use a virtual reality headset or augmented reality glasses to view the images.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008106331,"gmtCreate":1641378289978,"gmtModify":1676533607765,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Worrying","listText":"Worrying","text":"Worrying","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008106331","repostId":"1168647412","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001405827,"gmtCreate":1641293330898,"gmtModify":1676533593767,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001405827","repostId":"1127361669","repostType":4,"repost":{"id":"1127361669","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1641291181,"share":"https://ttm.financial/m/news/1127361669?lang=&edition=fundamental","pubTime":"2022-01-04 18:13","market":"us","language":"en","title":"5 Stocks To Watch For January 4, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1127361669","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings,","content":"<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For January 4, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For January 4, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-04 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MLKN":"MillerKnoll","JAZZ":"爵士制药","ASGN":"盎塞","ITCI":"Intra-Cellular Therapies Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127361669","content_text":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings, Inc. to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.ASGN Incorporated reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.Analysts are expecting MillerKnoll, Inc to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.Intra-Cellular Therapies, Inc. reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.Jazz Pharmaceuticals plc reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001405169,"gmtCreate":1641293271350,"gmtModify":1676533593759,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001405169","repostId":"1127361669","repostType":4,"repost":{"id":"1127361669","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1641291181,"share":"https://ttm.financial/m/news/1127361669?lang=&edition=fundamental","pubTime":"2022-01-04 18:13","market":"us","language":"en","title":"5 Stocks To Watch For January 4, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1127361669","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings,","content":"<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For January 4, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For January 4, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-04 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MLKN":"MillerKnoll","JAZZ":"爵士制药","ASGN":"盎塞","ITCI":"Intra-Cellular Therapies Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127361669","content_text":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings, Inc. to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.ASGN Incorporated reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.Analysts are expecting MillerKnoll, Inc to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.Intra-Cellular Therapies, Inc. reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.Jazz Pharmaceuticals plc reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9006654316,"gmtCreate":1641729568056,"gmtModify":1676533643182,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"It should eventually&nbsp;","listText":"It should eventually&nbsp;","text":"It should eventually","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006654316","repostId":"1198290127","repostType":4,"repost":{"id":"1198290127","kind":"news","pubTimestamp":1641702682,"share":"https://ttm.financial/m/news/1198290127?lang=&edition=fundamental","pubTime":"2022-01-09 12:31","market":"us","language":"en","title":"Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290127","media":"TheStreet","summary":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready","content":"<html><head></head><body><p>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?</p><p>Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.</p><p>Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1f77cd919bf55f9c7b79f631b0255910\" tg-width=\"1240\" tg-height=\"697\" referrerpolicy=\"no-referrer\"/><span>Figure 1: Apple Park in Cupertino, CA.</span></p><p><b>AAPL: the bull case</b></p><p>As Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.</p><p>But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.</p><p>One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.</p><p><b>AAPL: the bear case</b></p><p>Despite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.</p><p>I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.</p><p><b>The Apple Maven’s take</b></p><p>I continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.</p><p>That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.</p><p>As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can Apple Stock Reclaim $3 Trillion And Thrive In 2022?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan Apple Stock Reclaim $3 Trillion And Thrive In 2022?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-09 12:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple...</p>\n\n<a href=\"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AAPL":"苹果"},"source_url":"https://www.thestreet.com/apple/stock/can-apple-stock-reclaim-3-trillion-and-thrive-in-2022","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198290127","content_text":"A market cap of $3 trillion has, so far, proven to be a ceiling that Apple stock does not seem ready to break through yet. Can shares reclaim the milestone soon and head higher in 2022?Recently, Apple stock flirted with $3 trillion in market cap, but quickly dipped below $2.9 trillion — as the broad market reacted to monetary tightening that should now happen more rapidly than previously expected.Can shares of the Cupertino company finally find its way north in 2022 and meet the expectations of so many bulls on Wall Street? Or will bearishness take over during a year of rising interest rates and lingering inflation?Figure 1: Apple Park in Cupertino, CA.AAPL: the bull caseAs Apple stock climbed viciously between late November and early December, many Wall Street experts piled on in support of “AAPL $3T”. Wedbush’s Dan Ives, for example, has been talking about the market cap milestone since our conversation in Q3 of last year, at least.But other analysts have also hopped on the bullish bandwagon recently. Morgan Stanley upped its price target to $200 per share in November, while the JPMorgan research team saw Apple stock heading to $3.5 trillion in market cap over the next 12 months.One of the most vocal optimists came from the buy side. Loup’s Gene Munster thought that his previous price target had quickly become stale, and that $250 per share now seemed more reasonable. In his opinion, the multi-year opportunity in the metaverse will gain investor appreciation in the new year, which should reignite momentum that the stock had lost in the last few weeks of 2021.AAPL: the bear caseDespite the upbeat expectations described above, mostly supported by company-specific factors, the market rolled into 2022 with its guard up. The boogieman of the moment seems to be the Federal Reserve’s anticipated reaction to near-full employment and sticky inflation, which should lead to higher interest rates in the next several months.I have recently explained how tighter money supply can spell trouble for stocks that trade for relatively high multiples. While AAPL is no Tesla or Rivian, the stock’s forward P/E of nearly 30 times and only modest earnings growth expectations could be a drag for share price in 2022, as investors look for better deals in value and cyclical stocks.The Apple Maven’s takeI continue to think that Apple is a great stock to buy and hold for the long term. Under the leadership of a CEO (and former COO) that is driven by operational excellence, the company seems to be in very good hands. Better yet, demand for Apple’s products and services, as well as consumer appreciation for the brand, seem to be at or near an all-time high.That said, the setup for the first few weeks or months of 2022 looks challenging to me. Apple stock climbed relentlessly in 2020, and then again last year. Aided by a spike in pandemic-driven demand for tech devices and lavish liquidity in the system, AAPL recorded one of its best three years of returns ever between 2019 and 2021.As much as the metaverse and autonomous vehicles can and likely will support the company’s financial results over the next many years, I think that AAPL stock is overdue for a breather. While shares will likely climb back above $3 trillion and head much higher from there eventually, I am not so confident that this rally will happen in the immediate future.","news_type":1},"isVote":1,"tweetType":1,"viewCount":582,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008628705,"gmtCreate":1641434443039,"gmtModify":1676533615138,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Sounds fun","listText":"Sounds fun","text":"Sounds fun","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008628705","repostId":"1127622369","repostType":4,"repost":{"id":"1127622369","kind":"news","pubTimestamp":1641432970,"share":"https://ttm.financial/m/news/1127622369?lang=&edition=fundamental","pubTime":"2022-01-06 09:36","market":"us","language":"en","title":"Disney Allowed To Create Its Own Metaverse At Theme Parks","url":"https://stock-news.laohu8.com/highlight/detail?id=1127622369","media":"TheStreet","summary":"Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The ","content":"<html><head></head><body><p>Walt Disney received federal approval for a patent to create a virtual world at its theme parks.</p><p>The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to create its own virtual reality space at its theme parks.</p><p>Disney said the patent will be used to create a virtual world at its brick and mortar venues such as inside a theme park or Disney property.</p><p>The entertainment company already has over 300 patents that are used for its ride systems, live entertainment, interactive technology, special effects, fiber optics and advanced audio systems.</p><p>The metaverse is gaining traction among tech companies such as Meta Platforms (formerly Facebook) FB, Google, Apple and Microsoft.</p><p>Disney&#39;s patent could allow the entertainment company to make a virtual world simulator throughout the park and potentially include &#34;a handheld device configured for use by a user in the real-world venue and communicatively coupled to the computing platform.&#34;</p><p>The patent could include the use of mutiple projectors to shine animated or visual image onto 3-D objects instead of the typical two dimensional being used currently.</p><p>This technology means that customers would not have to use a virtual reality headset or augmented reality glasses to view the images.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Disney Allowed To Create Its Own Metaverse At Theme Parks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDisney Allowed To Create Its Own Metaverse At Theme Parks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-06 09:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle><strong>TheStreet</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to ...</p>\n\n<a href=\"https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIS":"迪士尼"},"source_url":"https://www.thestreet.com/investing/meta-verse-entertainment-digital-parks-lifestyle","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127622369","content_text":"Walt Disney received federal approval for a patent to create a virtual world at its theme parks.The Walt Disney Co. received approval from the United States Patent and Trademark Office on Dec. 28 to create its own virtual reality space at its theme parks.Disney said the patent will be used to create a virtual world at its brick and mortar venues such as inside a theme park or Disney property.The entertainment company already has over 300 patents that are used for its ride systems, live entertainment, interactive technology, special effects, fiber optics and advanced audio systems.The metaverse is gaining traction among tech companies such as Meta Platforms (formerly Facebook) FB, Google, Apple and Microsoft.Disney's patent could allow the entertainment company to make a virtual world simulator throughout the park and potentially include \"a handheld device configured for use by a user in the real-world venue and communicatively coupled to the computing platform.\"The patent could include the use of mutiple projectors to shine animated or visual image onto 3-D objects instead of the typical two dimensional being used currently.This technology means that customers would not have to use a virtual reality headset or augmented reality glasses to view the images.","news_type":1},"isVote":1,"tweetType":1,"viewCount":452,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008106331,"gmtCreate":1641378289978,"gmtModify":1676533607765,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Worrying","listText":"Worrying","text":"Worrying","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008106331","repostId":"1168647412","repostType":4,"isVote":1,"tweetType":1,"viewCount":433,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008774856,"gmtCreate":1641540591984,"gmtModify":1676533627233,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Might be the dip before another massive spike","listText":"Might be the dip before another massive spike","text":"Might be the dip before another massive spike","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008774856","repostId":"1198673233","repostType":4,"repost":{"id":"1198673233","kind":"news","pubTimestamp":1641537463,"share":"https://ttm.financial/m/news/1198673233?lang=&edition=fundamental","pubTime":"2022-01-07 14:37","market":"us","language":"en","title":"Bitcoin Drops Below $42,000 to Lowest Level Since September","url":"https://stock-news.laohu8.com/highlight/detail?id=1198673233","media":"Bloomberg","summary":"Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since Septem","content":"<html><head></head><body><p>Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.</p><p>The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% from its record near $69,000 reached Nov. 10. Second-largest Ether dropped as much as 8.3% to its lowest level since Sept. 30.</p><p>The retreat comes after minutes from the Federal Reserve’s December meeting, published Wednesday, flagged the chance of earlier- and faster-than-expected rate hikes as well as potential balance-sheet rundown.</p><p>“The Fed’s intention to reduce the balance sheet in Q1 2022 is the primary cause of this sell-off,” Fundstrat strategists said in a note Thursday. “Unfortunately, no immediate support looks likely ahead of September 2021 lows at $39,573, with breaks of that leading down to last summer’s May-July bottom.”</p><p><img src=\"https://static.tigerbbs.com/41d898d24996b0fecf381b56b677bbcf\" tg-width=\"1200\" tg-height=\"675\" width=\"100%\" height=\"auto\"/></p><p>Bitcoin gained about 60% last year, outperforming other asset classes amid a narrative that included institutional adoption, inflation protection and investment diversification. It’s struggled in recent weeks, though, amid a volatile period for financial markets. Spiking inflation is leading central banks to tighten monetary policy, threatening to reduce the liquidity tailwind that lifted a wide range of assets.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bitcoin Drops Below $42,000 to Lowest Level Since September</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBitcoin Drops Below $42,000 to Lowest Level Since September\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 14:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GBTC":"Grayscale Bitcoin Trust"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-07/bitcoin-drops-below-42-000-to-lowest-level-since-september","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198673233","content_text":"Bitcoin continued a weeks-long drop on Friday, falling below $42,000 to levels not seen since September.The largest cryptocurrency declined as much as 4.9% to $41,008, marking a tumble of about 40% from its record near $69,000 reached Nov. 10. Second-largest Ether dropped as much as 8.3% to its lowest level since Sept. 30.The retreat comes after minutes from the Federal Reserve’s December meeting, published Wednesday, flagged the chance of earlier- and faster-than-expected rate hikes as well as potential balance-sheet rundown.“The Fed’s intention to reduce the balance sheet in Q1 2022 is the primary cause of this sell-off,” Fundstrat strategists said in a note Thursday. “Unfortunately, no immediate support looks likely ahead of September 2021 lows at $39,573, with breaks of that leading down to last summer’s May-July bottom.”Bitcoin gained about 60% last year, outperforming other asset classes amid a narrative that included institutional adoption, inflation protection and investment diversification. It’s struggled in recent weeks, though, amid a volatile period for financial markets. Spiking inflation is leading central banks to tighten monetary policy, threatening to reduce the liquidity tailwind that lifted a wide range of assets.","news_type":1},"isVote":1,"tweetType":1,"viewCount":290,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001405827,"gmtCreate":1641293330898,"gmtModify":1676533593767,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001405827","repostId":"1127361669","repostType":4,"repost":{"id":"1127361669","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1641291181,"share":"https://ttm.financial/m/news/1127361669?lang=&edition=fundamental","pubTime":"2022-01-04 18:13","market":"us","language":"en","title":"5 Stocks To Watch For January 4, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1127361669","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings,","content":"<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For January 4, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For January 4, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-04 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MLKN":"MillerKnoll","JAZZ":"爵士制药","ASGN":"盎塞","ITCI":"Intra-Cellular Therapies Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127361669","content_text":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings, Inc. to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.ASGN Incorporated reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.Analysts are expecting MillerKnoll, Inc to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.Intra-Cellular Therapies, Inc. reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.Jazz Pharmaceuticals plc reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":283,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9001405169,"gmtCreate":1641293271350,"gmtModify":1676533593759,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9001405169","repostId":"1127361669","repostType":4,"repost":{"id":"1127361669","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1641291181,"share":"https://ttm.financial/m/news/1127361669?lang=&edition=fundamental","pubTime":"2022-01-04 18:13","market":"us","language":"en","title":"5 Stocks To Watch For January 4, 2022","url":"https://stock-news.laohu8.com/highlight/detail?id=1127361669","media":"Benzinga","summary":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings,","content":"<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Stocks To Watch For January 4, 2022</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Stocks To Watch For January 4, 2022\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2022-01-04 18:13</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Some of the stocks that may grab investor focus today are:</p><ul><li>Wall Street expects <b>SMART Global Holdings, Inc.</b> to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.</li><li><b>ASGN Incorporated</b> reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.</li><li>Analysts are expecting <b>MillerKnoll, Inc</b> to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.</li></ul><ul><li><b>Intra-Cellular Therapies, Inc.</b> reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.</li><li><b>Jazz Pharmaceuticals plc</b> reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.</li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MLKN":"MillerKnoll","JAZZ":"爵士制药","ASGN":"盎塞","ITCI":"Intra-Cellular Therapies Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1127361669","content_text":"Some of the stocks that may grab investor focus today are:Wall Street expects SMART Global Holdings, Inc. to report quarterly earnings at $2.00 per share on revenue of $460.17 million after the closing bell. SMART Global shares gained 2.8% to close at $73.00 on Monday.ASGN Incorporated reported a $350 million buyback program and also disclosed several changes to its leadership team. ASGN shares gained 0.5% to close at $124.06 on Monday.Analysts are expecting MillerKnoll, Inc to post quarterly earnings at $0.57 per share on revenue of $1.04 billion for the latest quarter. MillerKnoll shares slipped 0.1% to $39.80 in after-hours trading.Intra-Cellular Therapies, Inc. reported a $400 million common stock offering. Intra-Cellular Therapies shares dropped 6.9% to $48.45 in the after-hours trading session.Jazz Pharmaceuticals plc reported that the FDA has granted Orphan Drug Exclusivity for Xywav oral solution. Jazz Pharmaceuticals shares slipped 0.1% to $130.97 in after-hours trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":366,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005038359,"gmtCreate":1642118941195,"gmtModify":1676533682755,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005038359","repostId":"2203179956","repostType":4,"repost":{"id":"2203179956","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1642116616,"share":"https://ttm.financial/m/news/2203179956?lang=&edition=fundamental","pubTime":"2022-01-14 07:30","market":"us","language":"en","title":"WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool","url":"https://stock-news.laohu8.com/highlight/detail?id=2203179956","media":"Reuters","summary":"A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKl","content":"<html><head></head><body><p>A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.</p><p>WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.</p><p>The panel on Thursday strongly recommended Lilly&#39;s baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir&#39;s antibody therapy for non-severe patients at the highest risk of hospitalization.</p><p>So far, GSK-Vir&#39;s monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> offered lower protection in such tests.</p><p>The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body&#39;s natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.</p><p>The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.</p><p>French medical charity Medecins Sans Frontieres <a href=\"https://laohu8.com/S/MSF\">$(MSF)$</a> welcomed the United Nations agency&#39;s guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.</p><p>MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWHO Recommends Eli Lilly, GSK-Vir's Drugs, Widening COVID-19 Treatment Pool\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2022-01-14 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.</p><p>WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.</p><p>The panel on Thursday strongly recommended Lilly&#39;s baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir&#39;s antibody therapy for non-severe patients at the highest risk of hospitalization.</p><p>So far, GSK-Vir&#39;s monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and <a href=\"https://laohu8.com/S/REGN\">Regeneron Pharmaceuticals</a> offered lower protection in such tests.</p><p>The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body&#39;s natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.</p><p>The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.</p><p>French medical charity Medecins Sans Frontieres <a href=\"https://laohu8.com/S/MSF\">$(MSF)$</a> welcomed the United Nations agency&#39;s guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.</p><p>MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克","VIR":"Vir Biotechnology, Inc.","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4007":"制药","BK4535":"淡马锡持仓","BK4532":"文艺复兴科技持仓","LLY":"礼来","BK4551":"寇图资本持仓","BNTX":"BioNTech SE"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2203179956","content_text":"A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly , and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.WHO data shows Omicron, which is evading protection provided by many vaccines and therapies, has been identified in 149 countries. It is quickly replacing Delta as the dominant variant in several nations, forcing governments and scientists to bolster defences with testing, shots and therapies.The panel on Thursday strongly recommended Lilly's baricitinib, sold under brand name Olumiant, for patients with severe COVID-19 in combination with corticosteroids, while conditionally endorsed GSK-Vir's antibody therapy for non-severe patients at the highest risk of hospitalization.So far, GSK-Vir's monoclonal antibody therapy is the only one that has shown effectiveness against Omicron in lab tests, while similar treatments from Eli Lilly and Co and Regeneron Pharmaceuticals offered lower protection in such tests.The WHO experts noted that the effectiveness of monoclonal antibody treatments -- lab-generated compounds that mimic the body's natural defences -- against new variants such as Omicron was still uncertain, and said the guidelines for this class of medicine will be updated when additional data become available.The WHO guidelines, published in the British Medical Journal, also noted that evidence shows baricitinib improves survival rate and reduces the need for ventilation, with no observed increase in adverse effects.French medical charity Medecins Sans Frontieres $(MSF)$ welcomed the United Nations agency's guidelines, and said baricitinib can be a potential alternative to current WHO-recommended monoclonal antibody treatments that remain in short supply for governments and patients in many low- and middle-income countries.MSF also said that governments must take steps to ensure that patent monopolies do not stand in the way of access to the treatment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":335,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9008267150,"gmtCreate":1641462272566,"gmtModify":1676533617627,"author":{"id":"4104376232081940","authorId":"4104376232081940","name":"fariqsaid","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104376232081940","authorIdStr":"4104376232081940"},"themes":[],"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9008267150","repostId":"1179623263","repostType":4,"isVote":1,"tweetType":1,"viewCount":327,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}